AMGN vs JNJ: fair value comparison
Amgen Inc. and Johnson & Johnson · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMGN currently sits closer to the top of our discount ranking. AMGN carries the stronger quality grade.
| AMGN | JNJ | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $437.23 | $275.23 |
| 12-month range | $294.20–$438.12 | $185.08–$271.19 |
| Sector rank | #105 of 113 Healthcare | #110 of 113 Healthcare |
| Quality grade | B | F |
| Leverage | High | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: AMGN fair value analysis · JNJ fair value analysis